Showing posts with label outsourcing clinical trials. Show all posts
Showing posts with label outsourcing clinical trials. Show all posts

Monday, December 7, 2009

A Look Back at Partnerships in Clinical Trials Asia Pacific!

Last week, we held the First Annual Partnerships in Clinical Trials Asia Pacific. At this meeting, we heard from many of the professionals who work closely with the clinical trails in the region, as well as where the expect to see the region to go within the next few years. See some of the sessions here:

Focus on China

Tailoring Outsourcing Strategies for the Asia-Pacific Region – Functional Insourcing

The Sponsor-Site Relationship: Optimizing the CRO Partnership

How partnering with Japan CROs Can Benefit the Global & Asian Drug Development

Regional Regulatory Briefings – What It Takes to Get Your Regional Clinical Trial Going

Accelerating Patient Recruitment and Retention in Clinical Trials


Share this article with your social network, just click below to share now!


Monday, November 23, 2009

Covance Partners with RBM to Extend Biomarker Offering

According to this article in outsourcing-pharma.com Covance will outsource biomarker activities to Rules Based Medicine, which is a US based laboratory group. Demand for biomarker services and the use of biomarker analysis in clinical trials has increased dramatically, and so this couldn't come at a better time.

Before the deal took place Covance had also begun building biomarker capacity. Under the deal RBM will apply its multi-analyte profile (MAP) technologies to projects being carried out by Covance's customers.


Share this article with your social network, just click below to share now!


Friday, February 20, 2009

Is Outsourcing of Clinical Trials Faulty?

A recent article in the NY Times raises the question about the ethics of conducting clinical trials outside the US when these studies are meant to gather evidence for drug approval in the country.

The article which was written by several Duke University researchers and was published in the New England Journal of Medicine discusses how medication that is intended for the wealthy should not be tested on people in developing countries. The report questions whether or not testing drugs in developing countries is even relevant to American patients.

What are your thoughts?


Share this article with your social network, just click below to share now!